RANI THERAPEUTICS HOLDINGS-A (RANI)
US7530181004 - Common Stock
Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update
- Completed two equity offerings with total gross proceeds of approximately $20.0 million; cash runway extended into 3Q 2025 - - Announced new...
Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants
SAN JOSE, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage...
Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit
SAN JOSE, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage...
Rani Therapeutics to Participate in September Investor Conferences
SAN JOSE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage...
Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update
- Announced partnership with ProGen on development of RT-114, an oral GLP-1/GLP-2 dual agonist for the treatment of obesity - - Phase 1 study for RT-114...
Rani Therapeutics to Participate in August Investor Conferences
SAN JOSE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage...
Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering
SAN JOSE, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage...
Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment
~ New RT-114 obesity program combines ProGen’s FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to...
Rani Therapeutics to Participate in May Investor Conferences
SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage...
Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024
SAN JOSE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage...
RANI Stock Earnings: Rani Therapeutics Hldgs Beats EPS for Q1 2024
RANI stock results show that Rani Therapeutics Hldgs beat analyst estimates for earnings per share the first quarter of 2024.
RANI Stock Earnings: Rani Therapeutics Hldgs Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rani Therapeutics Hldgs (NASDAQ:RANI) just reported results for the first quart...
Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update
- Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Initiation of Phase 2 clinical trial for...
RANI Stock Earnings: Rani Therapeutics Hldgs Beats EPS for Q4 2023
RANI stock results show that Rani Therapeutics Hldgs beat analyst estimates for earnings per share the fourth quarter of 2023.
RANI Stock Earnings: Rani Therapeutics Hldgs Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rani Therapeutics Hldgs (NASDAQ:RANI) just reported results for the fourth quar...
Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update
- Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Announced Preclinical...
Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
SAN JOSE, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage...
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Rani Therapeutics Holdings, Inc. (NASDAQ: RANI)
/PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) on behalf of the company's...
Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist
- Transenteric delivery of incretin triagonist of GLP-1, GIP, glucagon receptors elicits rapid weight loss in animal study – - Preclinical data...
Rani Therapeutics CEO discloses purchase of 10K shares (NASDAQ:RANI)
Rani Therapeutics CEO purchases 10,000 shares worth $22,700, increasing ownership to 484,455 shares. 5 insider trades in the past 3 months.
Rani Therapeutics CEO Talat Imran purchases 5,000 shares (NASDAQ:RANI)
RANI's CEO, Talat Imran, acquires 5,000 shares in the company, totaling $12,850. Four insider trades occurred in the last three months.
Rani Therapeutics says CEO Imran buys 20K class A shares (NASDAQ:RANI)
RANI CEO Talat Imran purchased 20K class A shares at $2.05, contributing to the company's overall net insider buying activity of 56K shares.